10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[x]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended October 31, 2019
or
[  ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _____________ to _____________

Commission File Number 000-55569

PANAMERA HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	46-5707326
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

4180 Orchard Hill Drive, Edmond, OK	73025
(Address of principal executive offices)	(Zip Code)

(405) 413-5735

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [x] Yes     [  ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [x] Yes    [  ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[  ]	Accelerated filer	[  ]
Non-accelerated filer	[x]	Smaller reporting company	[x]
		Emerging growth company	[x]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) [x] YES     [   ] NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 

17,990,000 shares of common stock issued and outstanding as of December 13, 2019

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	12
Item 4.	Controls and Procedures	13
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Mine Safety Disclosures	14
Item 5.	Other Information	14
Item 6.	Exhibits	15
SIGNATURES		16

2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PANAMERA HEALTHCARE CORPORATION

Balance Sheets

(Unaudited)

	October 31,			July 31,
	2019			2019
ASSETS
Current Assets
Cash and cash equivalents	$	387		$	671
Total Current Assets		387			671
TOTAL ASSETS	$	387		$	671
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	3,250		$	4,303
Accrued interest - related party		7,335			6,238
Due to related party		92,401			80,101
Total Current Liabilities		102,986			90,642
TOTAL LIABILITIES		102,986			90,642
Stockholders’ Deficit
Preferred stock: 50,000,000 authorized; $0.0001 par value
no shares issued and outstanding		—			—
Common stock: 150,000,000 authorized; $0.0001 par value
17,990,000 shares issued and outstanding		1,799			1,799
Additional paid in capital		145,750			145,750
Accumulated deficit		(250,148	)		(237,520	)
Total Stockholders’ Deficit		(102,599	)		(89,971	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	387		$	671

The accompanying notes to the unaudited financial statements are an integral part of these statements.

3

PANAMERA HEALTHCARE CORPORATION

Statements of Operations

(Unaudited)

	For the
	Three Months Ended
	October 31,
	2019			2018
Operating Expenses
Professional fees	$	11,250		$	11,103
General and administration expenses		281			208
Total operating expenses		11,531			11,311
Net loss from operations		(11,531	)		(11,311	)
Other expense
Interest expense		(1,097	)		(744	)
Total other expense		(1,097	)		(744	)
Net loss before taxes		(12,628	)		(12,055	)
Income tax benefit		—			—
Net loss	$	(12,628	)	$	(12,055	)
Basic and diluted loss per common share	$	(0.00)		$	(0.00)
Weighted average number of common shares outstanding, basic and diluted		17,990,000			17,990,000

The accompanying notes to the unaudited financial statements are an integral part of these statements.

4

PANAMERA HEALTHCARE CORPORATION

Statements of Changes in Stockholders’ Deficit

(Unaudited)

For the Three Months Ended October 31, 2019

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, July 31, 2019		17,990,000	$	1,799	$	145,750	$	(237,520	)	$	(89,971	)
Net loss		—		—		—		(12,628	)		(12,628	)
Balance, October 31, 2019		17,990,000		1,799		145,750		(250,148	)		(102,599	)

For the Three Months Ended October 31, 2018

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, July 31, 2018		17,990,000	$	1,799	$	145,750	$	(207,203	)	$	(59,654	)
Net loss		—		—		—		(12,055	)		(12,055	)
Balance, October 31, 2018		17,990,000		1,799		145,750		(219,258	)		(71,709	)

The accompanying notes to the unaudited financial statements are an integral part of these statements.

5

PANAMERA HEALTHCARE CORPORATION

Statements of Cash Flows

(Unaudited)

	For the
	Three Months Ended
	October 31,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(12,628	)	$	(12,055	)
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		(1,053	)		(4,896	)
Accrued interest - related party		1,097			744
Net Cash Used In Operating Activities		(12,584	)		(16,207	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related party loans		12,300			13,500
Net Cash Provided by Financing Activities		12,300			13,500
Net change in cash and cash equivalents		(284	)		(2,707	)
Cash and cash equivalents, beginning of period		671			4,180
Cash and cash equivalents, end of period	$	387		$	1,473
Supplemental cash flow information
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—

The accompanying notes to the unaudited financial statements are an integral part of these statements.

6

PANAMERA HEALTHCARE CORPORATION

Notes to the Unaudited Interim Financial Statements

October 31, 2019

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

Panamera Healthcare Corporation (the “Company”) is a Nevada corporation incorporated on May 20, 2014. It is based in Oklahoma City, OK, USA. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is July 31.

The Company intends to offer management and consulting services to healthcare organizations that are increasingly facing various stresses including financial, organizational, and information technology challenges. To date, the Company’s activities have been limited to its formation and the raising of equity capital.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2019, as filed with the SEC on October 29, 2019.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of October 31, 2019, the Company has a loss from operations, an accumulated deficit and has not earned any revenues. The Company intends to fund operations through equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2020.

The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

7

NOTE 4 - RELATED PARTY TRANSACTIONS

Note Payable

On July 15, 2014, a corporation controlled by an officer and director committed $75,000 Promissory Note in the form of an unsecured line of credit. Any unpaid balance was due December 31, 2015. On April 15, 2019, the line of credit increased to $100,000 and was extended to December 31, 2019, at an annual interest rate of 5% and may be prepaid without penalty. The Company concluded the note modification was not a significant change and is not treating it as an extinguishment. During the three months ended October 31, 2019, the Company borrowed $12,300 and repayments under the line of credit to the Company were made in the amount of $0. As of October 31, 2019, the Company was obligated, for this interest-bearing loan with a balance of $92,401 and accrued interest of $7,335. The Company plans to pay the loan and interest back as cash flows become available. The remaining balance available under the line of credit is $7,599 as of October 31, 2019. For the three months ended October 31, 2019 and 2018, the Company paid $0 and $0, respectively, in interest on this note payable.

Other

The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder, who is also the CEO and President, of the Company to use at no charge.

8

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.   

FORWARD-LOOKING STATEMENTS

 

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Panamera Healthcare Corporation, unless otherwise indicated.

General Overview

We were incorporated under the laws of the State of Nevada on May 20, 2014. We intend to offer management and consulting services to healthcare organizations. We intend to focus on ambulatory surgical centers (ASCs) that currently have an incentive to be acquired by hospitals in order to increase compensation levels. We believe the short term strategy of converting to hospital based compensation is not sustainable because fundamental changes in the way healthcare is being provided are being undertaken by both government and private insurance carriers. The demographics of an aging population also mandate such changes to avoid economic disruption, healthcare rationing or unsustainable taxation.

We intend to offer management and consulting services to healthcare organizations. We intend to focus on ambulatory surgical centers (ASCs) that currently have an incentive to be acquired by hospitals in order to increase compensation levels. We believe the short term strategy of converting to hospital based compensation is not sustainable because fundamental changes in the way healthcare is being provided are being undertaken by both government and private insurance carriers.

Our address is 4180 Orchard Hill Drive, Edmond, OK 73025. Our telephone number is (405) 413-5735. Our corporate website is www.panamerahealth.com.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this report. Our unaudited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

9

Results of Operations

The following summary of our results of operations should be read in conjunction with our consolidated financial statements for the three months ended October 31, 2019, which are included herein.

Our operating results for the three months ended October 31, 2019 and 2018 and the changes between those periods for the respective items are summarized as follows

	Three Months Ended
	October 31,
	2019		2018		Changes ($)
Operating expenses	$	11,531	$	11,311	$	220
Interest expense	$	1,097	$	744	$	353
Net loss	$	12,628	$	12,055	$	573

During the three months ended October 31, 2019 and 2018, no revenues were recorded.

We had a net loss of $12,628 for the three months ended October 31, 2019, and $12,055 for the three months ended October 31, 2018. The increase in net loss of $573, was due to an increase in operating expenses of $220 and an increase in interest expenses of $353.

Operating expenses for the three months ended October 31, 2019 and 2018 were $11,531 and $11,311, respectively. The operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) and general and administrative expenses.

Interest expenses for the three months ended October 31, 2019 and 2018, represent interest expense to a related party on funds advanced to the Company.

Balance Sheet Data: 

	October 31, 2019			July 31, 2019
Cash	$	387		$	671
Current Assets	$	387		$	671
Current Liabilities	$	102,986		$	90,642
Working Capital (Deficiency)	$	(102,599	)	$	(89,971	)

As at October 31, 2019, our current assets were $387, and our current liabilities were $102,986 which resulted in working capital deficiency of $102,599. As of October 31, 2019, current assets were comprised of $387 in cash, compared to $671 in cash as of July 31, 2019. As of October 31, 2019, current liabilities were comprised of $102,986 in accounts payable and accrued liabilities of $3,250 and $99,736 in due to related parties and accrued interest, compared to $4,303 in accounts payable and accrued liabilities and $86,339 due to related party and accrued interest as of July 31, 2019.

As of October 31, 2019, our working capital deficiency increased by $12,628 from $89,971 on July 31, 2019, to $102,599 on October 31, 2019, primarily due to an increase in current liabilities of $12,344 and a decrease in current assets of $284.

 

10

Cash Flow Data:

	Three Months Ended
	October 31,
	2019			2018			Changes ($)
Cash Flows used in Operating Activities	$	(12,584	)	$	(16,207	)	$	3,623
Cash Flows provided by Financing Activities	$	12,300		$	13,500		$	(1,200	)
Net Change in Cash During Period	$	(284	)	$	(2,707	)	$	2,423

Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. For the three months ended October 31, 2019, net cash flows used in operating activities was $12,584, consisting of a net loss of $12,628, increased by a decrease in accounts payable and accrued liabilities of $1,053, and reduced by an increase in accrued interest due to related parties of $1,097. For the three months ended October 31, 2018, net cash flows used in operating activities was $16,207, consisting of a net loss of $12,055, increased by a decrease in accounts payable and accrued liabilities of $4,896 and reduced by an increase in accrued interest due to related parties of $744.

Cash Flows used in Investing Activities

During the three months ended October 31, 2019 and 2018, we had no cash used in investing activities.

Cash Flows from Financing Activities

We have financed our operations from the issuance of equity and loans from related parties. For the three months ended October 31, 2019, and 2018, we received $12,300 and $13,500 from advances from related party loans, respectively.

Going Concern

As of October 31, 2019, our company had a net loss of $12,628 and has earned no revenues. Our company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2020. The ability of our company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of our business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about our company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

11

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company”, we are not required to provide the information required by this Item.

12

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of October 31, 2019. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:

(1) lack of a functioning audit committee, (2) lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (3) inadequate segregation of duties consistent with control objectives; and (4) management is dominated by two individuals without adequate compensating controls.

A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended October 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

13

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party and which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

Item 1A. Risk Factors.

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

14

Item 6. Exhibits.

The following exhibits are included as part of this report:

Exhibit Number	Description
(3)	Articles of Incorporation and Bylaws
3.1	Articles of Incorporation (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)
3.2	Bylaws (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)
(14)	Code of Ethics
14.1	Code of Ethics for Directors, Officers, and Employees (incorporated by reference to exhibit 14.1 in our Registration Statement on Form S-1 filed on September 26, 2014)
14.2	Code of Ethics for CEO And Senior Financial Officers (incorporated by reference to exhibit 14.2 in our Registration Statement on Form S-1 filed on September 26, 2014)
(31)	Rule 13a-14 (d)/15d-14d) Certifications
31.1*	Section 302 Certification by the Principal Executive Officer
31.2*	Section 302 Certification by the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certifications
32.1**	Section 906 Certification by the Principal Executive Officer
32.2**	Section 906 Certification by the Principal Financial Officer and Principal Accounting Officer
101**	Interactive Data File
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

___________

*	Filed herewith.
**	Furnished herewith and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

15

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PANAMERA HEALTHCARE CORPORATION
	(Registrant)
Dated: December 16, 2019	/s/ Curtis Summers
	Curtis Summers
	President, Chief Executive Officer and Director
	(Principal Executive Officer)
Dated: December 16, 2019	/s/ Douglas G. Baker
	Douglas G. Baker
	Secretary, Chief Financial Officer, Treasurer and Director
	(Principal Financial Officer and Principal Accounting Officer)

16

EX-31

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 

I, Curtis Summers, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Panamera Healthcare Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 16, 2019

/s/ Curtis Summers

Curtis Summers

President, Chief Executive Officer and Director

(Principal Executive Officer)

EX-31

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 

I, Douglas G. Baker, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Panamera Healthcare Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 16, 2019

/s/ Douglas G. Baker

Douglas G. Baker

Secretary, Chief Financial Officer, Treasurer and Director

(Principal Financial Officer and Principal Accounting Officer)

EX-32

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Curtis Summers, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of Panamera Healthcare Corporation for the period ended October 31, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Panamera Healthcare Corporation.

Dated: December 16, 2019	/s/ Curtis Summers
	Curtis Summers
	President, Chief Executive Officer and Director (Principal Executive Officer)
	Panamera Healthcare Corporation

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Panamera Healthcare Corporation and will be retained by Panamera Healthcare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas G. Baker, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of Panamera Healthcare Corporation for the period ended October 31, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Panamera Healthcare Corporation.

Dated: December 16, 2019	/s/ Douglas G. Baker
	Douglas G. Baker
	Secretary, Chief Financial Officer, Treasurer and Director (Principal Financial Officer and Principal Accounting Officer)
	Panamera Healthcare Corporation

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Panamera Healthcare Corporation and will be retained by Panamera Healthcare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

XML

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 15, 2019	Oct. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 15, 2014
Related Party Transaction [Line Items]
Increase in line of credit	$ 100,000
Annual interest rate	5.00%
Amount borrowed from related party		$ 12,300	$ 13,500
Due to related party		92,401		$ 80,101
Accrued interest - related party		7,335		$ 6,238
Officer and director | Note Payable
Related Party Transaction [Line Items]
Promissory note amount					$ 75,000
Amount borrowed from related party		12,300
Net repayments under the line of credit		0
Due to related party		92,401
Accrued interest - related party		7,335
Remaining balance available under line of credit		7,599
Cash paid for interest		$ 0	$ 0

XML

Balance Sheets - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Current Assets
Cash and cash equivalents	$ 387	$ 671
Total Current Assets	387	671
TOTAL ASSETS	387	671
Current Liabilities
Accounts payable and accrued liabilities	3,250	4,303
Accrued interest - related party	7,335	6,238
Due to related party	92,401	80,101
Total Current Liabilities	102,986	90,642
TOTAL LIABILITIES	102,986	90,642
Stockholders' Deficit
Preferred stock: 50,000,000 authorized; $0.0001 par value no shares issued and outstanding	0	0
Common stock: 150,000,000 authorized; $0.0001 par value 17,990,000 shares issued and outstanding	1,799	1,799
Additional paid in capital	145,750	145,750
Accumulated deficit	(250,148)	(237,520)
Total Stockholders' Deficit	(102,599)	(89,971)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 387	$ 671

XML

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,628)	$ (12,055)
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	(1,053)	(4,896)
Accrued interest - related party	1,097	744
Net Cash Used In Operating Activities	(12,584)	(16,207)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related party loans	12,300	13,500
Net Cash Provided by Financing Activities	12,300	13,500
Net change in cash and cash equivalents	(284)	(2,707)
Cash and cash equivalents, beginning of period	671	4,180
Cash and cash equivalents, end of period	387	1,473
Supplemental cash flow information
Cash paid for interest	0	0
Cash paid for taxes	$ 0	$ 0

XML

Balance Sheets (Parentheticals) - $ / shares	Oct. 31, 2019	Jul. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued	17,990,000	17,990,000
Common stock, shares outstanding	17,990,000	17,990,000

XML

ORGANIZATION AND DESCRIPTION OF BUSINESS

3 Months Ended

Oct. 31, 2019

Organization And Description Of Business [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

Panamera Healthcare Corporation (the “Company”) is a Nevada corporation incorporated on May 20, 2014. It is based in Oklahoma City, OK, USA. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is July 31.

The Company intends to offer management and consulting services to healthcare organizations that are increasingly facing various stresses including financial, organizational, and information technology challenges. To date, the Company’s activities have been limited to its formation and the raising of equity capital.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Oct. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2019, as filed with the SEC on October 29, 2019.

XML

GOING CONCERN

3 Months Ended

Oct. 31, 2019

Going Concern [Abstract]

GOING CONCERN

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of October 31, 2019, the Company has a loss from operations, an accumulated deficit and has not earned any revenues. The Company intends to fund operations through equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2020.

The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML

Document and Entity Information - shares	3 Months Ended
	Oct. 31, 2019	Dec. 13, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	PANAMERA HEALTHCARE Corp
Entity Central Index Key	0001620749
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		17,990,000
Document Type	10-Q
Document Period End Date	Oct. 31, 2019
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Quarterly Report	true
Entity Address, Address Line One	4180 Orchard Hill Drive
Entity Address, City or Town	Edmond
Entity Address, State or Province	OK
City Area Code	405
Entity Address, Postal Zip Code	73025
Entity Current Reporting Status	Yes
Local Phone Number	413-5735
Entity Tax Identification Number	46-5707326
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	NV
Entity Shell Company	true
Entity File Number	000-55569

XML

Statements Of Changes In Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jul. 31, 2018	$ 1,799	$ 145,750	$ (207,203)	$ (59,654)
Balance (in shares) at Jul. 31, 2018	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(12,055)	(12,055)
Balance at Oct. 31, 2018	$ 1,799	145,750	(219,258)	(71,709)
Balance (in shares) at Oct. 31, 2018	17,990,000
Balance at Jul. 31, 2019	$ 1,799	145,750	(237,520)	(89,971)
Balance (in shares) at Jul. 31, 2019	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(12,628)	(12,628)
Balance at Oct. 31, 2019	$ 1,799	$ 145,750	$ (250,148)	$ (102,599)
Balance (in shares) at Oct. 31, 2019	17,990,000

XML

RELATED PARTY TRANSACTIONS

3 Months Ended

Oct. 31, 2019

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 4 - RELATED PARTY TRANSACTIONS

Note Payable

On July 15, 2014, a corporation controlled by an officer and director committed $75,000 Promissory Note in the form of an unsecured line of credit. Any unpaid balance was due December 31, 2015. On April 15, 2019, the line of credit increased to $100,000 and was extended to December 31, 2019, at an annual interest rate of 5% and may be prepaid without penalty. The Company concluded the note modification was not a significant change and is not treating it as an extinguishment. During the three months ended October 31, 2019, the Company borrowed $12,300 and repayments under the line of credit to the Company were made in the amount of $0. As of October 31, 2019, the Company was obligated, for this interest-bearing loan with a balance of $92,401 and accrued interest of $7,335. The Company plans to pay the loan and interest back as cash flows become available. The remaining balance available under the line of credit is $7,599 as of October 31, 2019. For the three months ended October 31, 2019 and 2018, the Company paid $0 and $0, respectively, in interest on this note payable.

Other

The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder, who is also the CEO and President, of the Company to use at no charge.

XML

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Operating Expenses
Professional fees	$ 11,250	$ 11,103
General and administration expenses	281	208
Total operating expenses	11,531	11,311
Net loss from operations	(11,531)	(11,311)
Other expense
Interest expense	(1,097)	(744)
Total other expense	(1,097)	(744)
Net loss before taxes	(12,628)	(12,055)
Income tax benefit	0	0
Net loss	$ (12,628)	$ (12,055)
Basic and diluted loss per common share (in dollars per share)	$ (0.00)	$ (0.00)
Weighted average number of common shares outstanding, basic and diluted (in shares)	17,990,000	17,990,000

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Oct. 31, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2019, as filed with the SEC on October 29, 2019.